Accurate Wealth Management 13F: Adds $1.4M to JNJ Stake
Key Points
- Accurate Wealth Management added 5,437 shares of Johnson & Johnson (NYSE:JNJ) during the quarter, bringing its total holding to 37,817 shares worth about $9.4 million.
- Johnson & Johnson shares recently traded around $259.42, sitting roughly 7.7% below their 52-week high of $281.07.
- Four company executives sold a combined total of over 187,000 shares between August and September 2026.
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Accurate Wealth Management boosted its stake in Johnson & Johnson (NYSE:JNJ) by 16.8% during the quarter, according to a Form 13F filing on October 20, 2026.
JNJ
Johnson & Johnson
Accurate Wealth Management vs. the S&P 500
Hypothetical returns from Accurate Wealth Management's disclosed trades, not real profit or advice. How we model this.
What Changed in Accurate Wealth Management's Johnson & Johnson Position
The firm added 5,437 shares of the healthcare giant during the period, growing its total holdings from 32,380 shares up to 37,817 shares. The updated stake carried a reported value of $9,421,297 at the time of the filing.
Other Institutional Activity in Johnson & Johnson
Other large funds also manage sizable positions in the healthcare giant. State Farm Mutual Automobile Insurance Co kept its massive holding steady at 31,590,952 shares, which were valued at approximately $8,193,428,847.
Johnson & Johnson Stock Up 1.5%
Johnson & Johnson shares recently traded around $259.42 as of October 21, 2026, roughly equal to the $259.36 close on the filing date. The stock trades about 7.7% below its 52-week high of $281.07 and roughly 40.5% above its 52-week low of $184.66.
Recent Earnings
Johnson & Johnson reported trailing twelve-month revenue of $99.33 billion alongside earnings of $6.59 per share. The company generated a net profit margin of 16.2% and anticipates its next earnings release on January 26, 2027.
Dividend
The company pays an annual dividend rate of $5.36 per share, giving it a dividend yield of 2.11%. Its dividend payout ratio stands at 60.7%.
Insider Buying and Selling at Johnson & Johnson
Several company insiders trimmed their holdings over the late summer. Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, for $4,090,960. Chief Executive Officer Joaquin Boix Duato sold 123,291 shares on August 13, 2026, valued at $32,199,927. Officer Jennifer L Taubert sold 15,000 shares at $263.36 apiece on August 17, 2026, totaling $3,950,400. Finally, officer Timothy Schmid sold 33,597 shares at $274.74 each on September 2, 2026, for a total of $9,230,440.
Analysts Set New Price Targets
Wall Street firms updated their outlooks on the stock in mid-October 2026. On October 14, 2026, Leerink Partners maintained its Outperform rating while lowering its target to $272.00. Wells Fargo maintained its Overweight rating on October 14, 2026, dropping its target to $275.00 before raising it to $287.00 on October 16, 2026. RBC Capital maintained an Outperform rating with a lowered target of $280.00 on October 14, 2026. Morgan Stanley kept an Overweight rating and adjusted its target to $292.00 on October 15, 2026. The stock carries a consensus buy rating across 22 analyst opinions with a mean target price of $279.41.
About Johnson & Johnson
Johnson & Johnson researches, develops, manufactures, and sells a wide array of healthcare products across the globe. Operating through its Innovative Medicine and MedTech segments, the New Brunswick, New Jersey-based firm develops treatments and medical devices that serve patients worldwide.
Bottom Line
Institutional interest in major healthcare mainstays remains strong as investors monitor upcoming earnings scheduled for late January 2027. Watch for further SEC filings and analyst updates to see how large funds adjust their positions moving forward.
Related Filing Alerts
Source: Accurate Wealth Management's 13F filing on $JNJ (Oct 20, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts